Skip to main content
. 2022 Jan 26;28(1):2–13. doi: 10.1097/PPO.0000000000000567

FIGURE 1.

FIGURE 1

Treatment schema of selected venetoclax-based regimens in AML. AZA indicates azacytidine; a/w, alternating with; Clad, cladribine; cy, cycle; D or d, day; DEC, decitabine; DL, dose level; i, inhibitor; IDA, idarubicin; LDAC, low-dose cytarabine; q, every; VEN, venetoclax.